VGI Health Technology Limited, a biotechnology company, engages in the research, development, distribution, and marketing of various health and therapeutic products, and technologies.
VGI Health Technology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.25|
|52 Week High||AU$0.15|
|52 Week Low||AU$0.30|
|1 Month Change||31.58%|
|3 Month Change||66.67%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||13.64%|
Recent News & Updates
|VTL||AU Pharmaceuticals||AU Market|
Return vs Industry: Insufficient data to determine how VTL performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VTL performed against the Australian Market.
Stable Share Price: Insufficient data to determine VTL's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine VTL's volatility change over the past year.
About the Company
VGI Health Technology Limited, a biotechnology company, engages in the research, development, distribution, and marketing of various health and therapeutic products, and technologies. It offers drugs and wellbeing supplements. The company also develops nE1-Heart for treatment of hyperlipidaemia; and nE1-Elite that reduce delayed onset muscle soreness, enhance muscle recovery, and provide exercise endurance and maintenance of muscle power.
VGI Health Technology Fundamentals Summary
|VTL fundamental statistics|
Is VTL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VTL income statement (TTM)|
|Cost of Revenue||AU$13.97k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.028|
|Net Profit Margin||0.00%|
How did VTL perform over the long term?See historical performance and comparison
Is VGI Health Technology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VTL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VTL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VTL is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: VTL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VTL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VTL is overvalued based on its PB Ratio (4.1x) compared to the AU Pharmaceuticals industry average (3.5x).
How is VGI Health Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VGI Health Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has VGI Health Technology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VTL is currently unprofitable.
Growing Profit Margin: VTL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VTL is unprofitable, but has reduced losses over the past 5 years at a rate of 85.8% per year.
Accelerating Growth: Unable to compare VTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: VTL has a negative Return on Equity (-46.67%), as it is currently unprofitable.
How is VGI Health Technology's financial position?
Financial Position Analysis
Short Term Liabilities: VTL's short term assets (A$339.3K) do not cover its short term liabilities (A$1.2M).
Long Term Liabilities: VTL has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: VTL's debt to equity ratio (2.5%) is considered satisfactory.
Reducing Debt: VTL's debt to equity ratio has increased from 0.01% to 2.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VTL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VTL has less than a year of cash runway if free cash flow continues to grow at historical rates of 46.2% each year.
What is VGI Health Technology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VTL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VTL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VTL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Glenn Tong, FACID, serves as Chief Executive Officer and Managing Director of VGI Health Technology Limited (formerly known as Azure Health Technology Limited). He was Director of Azure Health Technolo...
CEO Compensation Analysis
Compensation vs Market: Glenn's total compensation ($USD235.42K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Insufficient data to compare Glenn's compensation with company performance.
Experienced Board: VTL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: VTL only recently listed within the past 12 months.
VGI Health Technology Limited's employee growth, exchange listings and data sources
- Name: VGI Health Technology Limited
- Ticker: VTL
- Exchange: NSX
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$34.562m
- Shares outstanding: 138.25m
- Website: https://vgiht.com
- VGI Health Technology Limited
- 19-29 Martin Place
- Suite 03
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 07:05|
|End of Day Share Price||2021/10/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.